Intellipharmaceutics International Inc.

IPCI.H

CA4581733090

Pharmaceuticals

Delayed Toronto S.E. Other stock markets 12:00:00 2024-03-21 pm EDT			5-day change	1st Jan Change
0.08 ^CAD	-.--%		-11.11%	+6.67%

Jan. 03	IntelliPharmaCeutics International Receives Conditional Approval For TSXV Listing	MT
2023	Intellipharmaceutics International Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2023	CI

Intellipharmaceutics: Fiscal Q2 Earnings Snapshot

July 21, 2022 at 03:13 pm EDT

TORONTO (AP) _ Intellipharmaceutics International Inc. (IPCIF) on Thursday reported a loss of $841,000 in its fiscal second quarter.

On a per-share basis, the Toronto-based company said it had a loss of 3 cents. Losses, adjusted for non-recurring gains, were 5 cents per share.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IPCIF at https://www.zacks.com/ap/IPCIF

Latest news about Intellipharmaceutics International Inc.

IntelliPharmaCeutics International Receives Conditional Approval For TSXV Listing	Jan. 03	MT
Intellipharmaceutics International Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2023	23-10-16	CI
Intellipharmaceutics International Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2023	23-07-14	CI
IntelliPharmaCeutics International Fiscal Q2 Loss Narrows on Higher Revenue	23-07-14	MT
Intellipharmaceutics International Narrows Fiscal Q1 Loss, Revenue Rises	23-06-06	MT
Intellipharmaceutics International Inc. Brief: Recorded net loss for Q1 of US$355,738 or $0.01 per common shar	23-06-06	MT
Intellipharmaceutics International Inc. Auditor Raises 'Going Concern' Doubt	23-06-04	CI
Intellipharmaceutics International Inc. Reports Earnings Results for the First Quarter Ended February 28, 2023	23-06-04	CI
Intellipharmaceutics International Inc. Brief: Announcing Cease Trade Order	23-03-07	MT
North American Morning Briefing : More Fed -3-	23-03-03	DJ
Ontario Securities Commission Denies Intellipharmaceutics' Application for Management Cease Trade Order	23-02-08	MT
Intellipharmaceutics International Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022	22-10-14	CI
Intellipharmaceutics International Fiscal Q3 Loss Widens	22-10-14	MT
North American Morning Briefing : All Eyes on Bank -2-	22-10-14	DJ
North American Morning Briefing : Stock Futures -2-	22-07-22	DJ
Intellipharmaceutics International Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2022	22-07-21	CI
North American Morning Briefing : Bank Earnings -2-	22-07-14	DJ
Intellipharmaceutics International Inc. Reports Earnings Results for the First Quarter Ended February 28, 2022	22-04-14	CI
IntelliPharmaCeutics International Fiscal Q1 Loss Narrows	22-04-14	MT
Earnings Flash (IPCIF) INTELLIPHARMACEUTICS INTERNATIONAL Reports Q1 Loss $-0.03	22-04-14	MT
North American Morning Briefing : Stock Futures -3-	22-02-28	DJ
Intellipharmaceutics International Inc. Auditor Raises 'Going Concern' Doubt	22-02-27	CI
Intellipharmaceutics International Inc. Reports Earnings Results for the Full Year Ended November 30, 2021	22-02-27	CI
Intellipharmaceutics International Inc. Announces Kenneth Keirstead, A Member of Board of Directors, Passed Away	22-01-13	CI
Intellipharmaceutics International Inc. Reports Earnings Results for the Third Quarter Ended August 31, 2021	21-10-15	CI

Chart Intellipharmaceutics International Inc.

Duration

Period

Chart Intellipharmaceutics International Inc.

More charts

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. Its product portfolio includes Oxycodone Hydrochloride ER, Regabatin, Dexmethylphenidate ER, Metformin ER, Venlafaxine ER, Pantoprazole ER, Quetiapine ER, Lamotrigine ER, Levetiracetam ER, Desvenlafaxine ER, Ranolazine ER, and Carvedilol ER. Its product portfolio includes both new products and controlled-release generic products. It also provides analytical services.

Sector

Pharmaceuticals

Calendar

2024-07-16 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
INTELLIPHARMACEUTICS INTERNATIONAL INC.	+6.67%	1.93M
ELI LILLY AND COMPANY	+27.97%	672B
NOVO NORDISK A/S	+23.76%	550B
JOHNSON & JOHNSON	-7.02%	351B
MERCK & CO., INC.	+14.85%	317B
ABBVIE INC.	+6.25%	292B
ASTRAZENECA PLC	+2.02%	211B
NOVARTIS AG	-0.52%	203B
ROCHE HOLDING AG	-10.31%	194B
PFIZER, INC.	-11.81%	144B